Novo Nordisk secured the long-awaited U.S. FDA approval for Awiqli (insulin icodec) injection, the first and only once-weekly, long-acting basal insulin for type 2 diabetes. The decision follows a regulatory process that began in 2023 and mirrored success in other territories, expanding the range of basal options beyond daily injections for patients and payers.